tbuckley/cabot-search huggingface dataset:
Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse.
Authors: Sarah Maria Rudman, Kathryn P. Gray, Julie Kasperzyk, Edward Giovannucci, Michael Pitt, Massimo F. Loda, Lorelei Mucci, Christopher Sweeney
Journal: Journal of Clinical Oncology (2012)

4555 Background: The metabolic syndrome (MS) has been implicated in the development of prostate cancer (PC). In our previous study of a Veterans’ Administration (VA) cohort, MS was associated with a shorter duration of PC control with ADT. We report the impact of MS on overall survival (OS) and PC specific death for a cohort of patients with biochemical relapse. Methods: 273 pts (64 VA pts and 209 pts from Health Professionals Follow up Study) treated with ADT for biochemical recurrence post radiation or prostatectomy for PC were included. The modified Adult Treatment Panel III criteria for MS was used to identify patients with MS status prior to the commencement of ADT. Cox models tested for association of MS status with OS or time to PC specific death. With 42% overall death rate, 31% MS prevalence, there was 90% power to detect HR= 1.81 (type I error rate =0.05). Results: 31% pts (84/273) had MS and 15% pts (40/273) died of PC. Median follow-up was 9.5 years. The median OS with and without MS was 7.4 and 11.2 years respectively. Patients with hypertension, being African American, having diabetes and age were associated with increased risk of death from any causes, while hypertension and being African American were also associated with increased risk of PC specific death. A multivariate Cox regression model adjusted for age at diagnosis, race, definitive local therapy (RT vs. RP), PSA at diagnosis and Gleason score revealed MS was associated with a significantly increased risk of death from any cause and PC specific death (Table). Conclusions: In men receiving ADT for biochemically recurrent androgen dependent PC, the presence of MS at the commencement of ADT is associated with an increased risk of death from any cause as well as prostate cancer specifically. [Table: see text]
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Authors: K.L. Jhaveri, X.V. Wang, V. Makker, S.-W. Luoh, E.P. Mitchell, J.A. Zwiebel, E. Sharon, R.J. Gray, S. Li, L.M. McShane, L.V. Rubinstein, D. Patton, P.M. Williams, S.R. Hamilton, B.A. Conley, C.L. Arteaga, L.N. Harris, P.J. O’Dwyer, A.P. Chen, K.T. Flaherty
Journal: Annals of Oncology (2019)

BackgroundThe National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors.MethodsEligible patients had HER2 amplification at a copy number (CN) >7 based on targeted next-generation sequencing (NGS) with a custom Oncomine AmpliSeq™ (ThermoFisher Scientific) panel. Patients with prior trastuzumab, pertuzumab or T-DM1 treatment were excluded. Patients received T-DM1 at 3.6 mg/kg i.v. every 3 weeks until toxicity or disease progression. Tumor assessments occurred every three cycles. The primary end point was centrally assessed objective response rate (ORR). Exploratory end points included correlating response with HER2 CN by NGS. The impact of co-occurring genomic alterations and PTEN loss by immunohistochemistry were also assessed.ResultsThirty-eight patients were enrolled and 36 included in efficacy analysis. Median prior therapies in the metastatic setting was 3 (range 0–9; unknown in one patient). Median HER2 CN was 17 (range 7–139). Partial responses were observed in two (5.6%) patients: one mucoepidermoid carcinoma of parotid gland and one parotid gland squamous cell cancer. Seventeen patients (47%) had stable disease including 8/10 (80%) with ovarian and uterine carcinomas, with median duration of 4.6 months. The 6-month progression-free survival rate was 23.6% [90% confidence interval 14.2% to 39.2%]. Common toxicities included fatigue, anemia, fever and thrombocytopenia with no new safety signals. There was a trend for tumor shrinkage with higher levels of gene CN as determined by the NGS assay.ConclusionT-DM1 was well tolerated. While this subprotocol did not meet the primary end point for ORR in this heavily pre-treated diverse patient population, clinical activity was seen in salivary gland tumors warranting further study in this tumor type in dedicated trials.
Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients
Authors: Bei Jia, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng
Journal: Blood (2017)
Quality in Biliary and Pancreatic Endoscopy Meeting
Authors: N Almeida, N Canena, M Areia
Journal: Endoscopy (2019)

One of the main goals of the Portuguese Society of Digestive Endoscopy (SPED) since its foundation is to contribute to increase quality in digestive endoscopy. Last year a meeting about quality in upper endoscopy took place In Lisbon. In 2019 we decided the focus would be in pancreatic and biliary endoscopy, mainly ERCP but also endoscopic ultrasonography. We will debate some of the performance measures suggested in the 2018 publication “Performance measures for ERCP and endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative” [1]. This one day meeting will have presentations on issues like: How to audit quality in pancreatobiliary endoscopy; training in ERCP and endoscopic ultrasonography; approach to the patient before pancreatobiliary endoscopy; how to increase quality during intervention; critical review of the ESGE performance measures; can we decrease technical failures and adverse events; how to achieve better results during intervention. A final quiz would test our participants knowledge and attention during the meeting.
Surgery, radiation, and systemic therapies in patients with metastatic melanoma.
Authors: Song Wang, Zhongyun Zhao, Beth Barber, Volker Jean Wagner
Journal: Journal of Clinical Oncology (2012)

e19044 Background: To describe treatment patterns with surgery, radiation, and systemic (drug) therapies in patients with metastatic melanoma in the U.S. Methods: Using a large U.S. medical claims database, patients were identified between 2005 and 2010 using ≥2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and ≥2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx). The index date was the first date of metastasis diagnosis. Patients were followed from the index date to death, disenrollment, or end of the study period (6/30/2010), whichever occurred first. Surgery, radiation, and systemic therapies were examined descriptively. Factors influencing treatment were examined using a logistic regression separately for surgery, radiation, and systemic therapy. Results: A total of 2,546 patients with metastatic melanoma were included in the analyses. Mean (± standard deviation) age was 60.6 (± 14.0) years old with 22.8% under 50 and 36.5% were female. Overall, 66.8% of patients had cancer treatment related surgery, 38.7% received systemic therapies, 44.7% received radiation, and 17.7% of patients received all three treatments. Logistic regressions revealed that patients with lung (p &lt;.0001), brain (p &lt;.0001), liver (p &lt;.0001), or bone (p &lt;.0001) metastases were less likely to have surgeries; patients with lung (p = 0.04), brain (p &lt; 0.001), or liver metastases (p = 0.03) were more likely to receive systemic therapies; as expected patients with brain (p &lt; 0.0001) or bone metastases (p &lt; 0.0001) were more likely to have radiation therapy. Patients being treated by oncologists were more likely to receive systemic therapy (p &lt; 0.0001) or radiation (p &lt; 0.0001) while patients being treated by dermatologists were more likely to receive surgery subsequently (p = 0.002). Older age and female gender were associated with a lower likelihood to receive surgery, systemic, or radiation therapy. Conclusions: Sites of metastases and treating physician specialty might influence treatments for patients with metastatic melanoma.
What You Ought To Know About Your Baby.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical applications of biomaterials
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium
Authors: Lauren C. Peres, Adrianne R. Mallen, Mary K. Townsend, Elizabeth M. Poole, Britton Trabert, Naomi E. Allen, Alan A. Arslan, Laure Dossus, Renée T. Fortner, Inger T. Gram, Patricia Hartge, Annika Idahl, Rudolf Kaaks, Marina Kvaskoff, Anthony M. Magliocco, Melissa A. Merritt, J. Ramón Quirós, Anne Tjonneland, Antonia Trichopoulou, Rosario Tumino, Carla H. van Gils, Kala Visvanathan, Nicolas Wentzensen, Anne Zeleniuch-Jacquotte, Shelley S. Tworoger
Journal: Cancer Research (2019)

Growing epidemiologic evidence supports chronic inflammation as a mechanism of ovarian carcinogenesis. An association between a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has been consistently observed, yet, potential heterogeneity of this association by tumor and patient characteristics has not been adequately explored. In this study, we pooled data from case-control studies nested within six cohorts in the Ovarian Cancer Cohort Consortium (OC3) to examine the association between CRP and epithelial ovarian cancer risk overall, by histologic subtype and by participant characteristics. CRP concentrations were measured from prediagnosis serum or plasma in 1,091 cases and 1,951 controls. Multivariable conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI). When CRP was evaluated using tertiles, no associations with ovarian cancer risk were observed. A 67% increased ovarian cancer risk was found for women with CRP concentrations >10 mg/L compared with <1 mg/L (OR = 1.67; 95% CI = 1.12-2.48). A CRP concentration >10 mg/L was positively associated with risk of mucinous (OR = 9.67; 95% CI = 1.10-84.80) and endometrioid carcinoma (OR = 3.41; 95% CI = 1.07-10.92), and suggestively positive, although not statistically significant, for serous (OR = 1.43; 95% CI = 0.82-2.49) and clear cell carcinoma (OR = 2.05; 95% CI = 0.36-11.57;
Comparative effectiveness of regimens of first-line platinum-based chemotherapy for advanced lung squamous cell carcinoma.
Authors: Kuo-Hsing Chen
Journal: Journal of Clinical Oncology (2012)

e18034 Background: Platinum-based cytotoxic chemotherapy remains the standard first-line therapy for patients with lung squamous cell carcinoma. This study aims to compare the effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma in the general population in Taiwan. Methods: We searched the Taiwan Cancer Registry database and the claim database of National Health Insurance, Taiwan for patients with newly diagnosed advanced lung squamous cell carcinoma from 2004 to 2007. Patients who received first-line combination chemotherapy with a platinum compound (cisplatin or carboplatin) plus either gemcitabine (G), docetaxel (D), paclitaxel (T), or vinorelbine (V) were included in the study. Overall survival (OS) was defined as the duration from the start of chemotherapy to death. Kaplan-Meier method was used to estimate the survival, which was univariately compared by the log-rank test. The Cox’s proportional hazard model was used to estimate the adjusted hazard ratios in multivariate analyses. Results: A total of 935 patients with advanced lung squamous cell carcinoma received first-line chemotherapy with a platinum compound (P) plus either G (57.6%), D (14.9%), T (11.3%), or V (16.0%). The proportion of elderly patients (age ≥ 70) who received P+D is lower than that of P+G, P+T, or P+V (35.71% vs 47.68%, 53.77%, 48.00% respectively, p = 0.0264). Patients who received P+G, P+D, P+T, or P+V had similar OS (median, 8.6 vs. 7.9 vs. 8.8 vs. 8.1 months, respectively; p = 0.969). Subgroup analyses based on age (≥ 70 or &lt; 70), gender, stage (IIIB or IV by AJCC 6 th edition), and the use of cisplatin revealed no differences in OS, either. In multivariate analyses adjusting for age, gender, and stage, the first-line chemotherapy regimen was still not a predictor of OS. With P+G as the reference group, the adjusted hazard ratios of P+D, P+T, and P+V were 1.02, 0.96, 1.03, respectively (p = 0.945). Conclusions: In patients with advanced lung squamous cell carcinoma, different treatment regimens did not have significant impact on the survival outcomes
Knowing Better and Doing Better to Advance Women in Academic Surgery
Authors: Christy Harris Lemak
Journal: JAMA Network Open (2019)

Julie A. Thompson-Burdine, BA; Dana A. Telem, MD, MPH; Jennifer F. Waljee, MD, MPH; Erika A. Newman, MD; Dawn M. Coleman, MD; Hadley I. Stoll, BS; Gurjit Sandhu, PhD
A randomized pilot study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer
Authors: P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, K. Y. Tsang, J. Schlom, W. L. Dahut
Journal: Journal of Clinical Oncology (2006)

2531 Background: Docetaxel has activity against androgen insensitive prostate cancer (AIPC) and preclinical studies have demonstrated that taxane-based chemotherapy can enhance antitumor response of vaccines. The primary objective of this study was to determine: if concurrent docetaxel (with dexamethasone) had any effect on generating an immune response to a prostate cancer vaccine in patients with metastatic AIPC; secondary endpoints werewhether vaccine could be given safely with docetaxel, and the clinical outcome of the treatment regimen. Methods: The vaccination regimen was composed of (1) recombinant vaccinia virus (rV) that expresses the prostate-specific antigen gene (rV-PSA) admixed with (2) rV that expresses the B7.1 costimulatory gene (rV-B7.1), and (3) sequential booster vaccinations with recombinant fowlpox virus containing the PSA gene (rF-PSA). Patients received GM-CSF with each vaccination. Twenty-eight patients with metastatic AIPC were randomized to receive either vaccine and weekly docetaxel or vaccine alone. Patients on the vaccine alone arm were allowed to cross over to receive docetaxel alone at time of disease progression. An ELISPOT assay for IFN-gamma production was used to monitor immune responses for PSA-specific T cells. Results: The median increase in these T-cell precursors to PSA was 3.33-fold in both arms following 3 months of therapy. In addition, immune responses to other prostate cancer associated tumor antigens were also detected post-vaccination. Eleven patients who progressed on vaccine alone crossed over to receive docetaxel at time of progression. Median PFS on docetaxel was 6.1 months after receiving vaccine compared to 3.7 months with the same regimen in a historical control. Conclusions: This is the first clinical trial to demonstrate that docetaxel can be administered safely with immunotherapy, and without inhibiting vaccine specific T-cell responses. Furthermore, patients previously vaccinated with an anticancer vaccine may respond longer to docetaxel compared with a historical control of patients receiving docetaxel alone. Larger prospective clinical studies will be required to validate these findings. No significant financial relationships to disclose.
Prospective Association Among Diabetes Diagnosis, HbA1c, Glycemia, and Frailty Trajectories in an Elderly Population
Authors: Gloria A. Aguayo, Adam Hulman, Michel T. Vaillant, Anne-Françoise Donneau, Anna Schritz, Saverio Stranges, Laurent Malisoux, Laetitia Huiart, Michèle Guillaume, Séverine Sabia, Daniel R. Witte
Journal: Diabetes Care (2019)

OBJECTIVE Frailty is a dynamic state of vulnerability in the elderly. We examined whether individuals with overt diabetes or higher levels of HbA1c or fasting plasma glucose (FG) experience different frailty trajectories with aging. RESEARCH DESIGN AND METHODS Diabetes, HbA1c, and FG were assessed at baseline, and frailty status was evaluated with a 36-item frailty index every 2 years during a 10-year follow-up among participants from the English Longitudinal Study of Ageing (ELSA). Mixed-effects models with age as time scale were used to assess whether age trajectories of frailty differed as a function of diabetes, HbA1c, and FG. RESULTS Among 5,377 participants (median age [interquartile range] 70 [65, 77] years, 45% men), 35% were frail at baseline. In a model adjusted for sex, participants with baseline diabetes had an increased frailty index over aging compared with those without diabetes. Similar findings were observed with higher levels of HbA1c, while FG was not associated with frailty. In a model additionally adjusted for income, social class, smoking, alcohol, and hemoglobin, only diabetes was associated with an increased frailty index. Among nonfrail participants at baseline, both diabetes and HbA1c level were associated with a higher increased frailty index over time. CONCLUSIONS People with diabetes or higher HbA1c levels at baseline had a higher frailty level throughout later life. Nonfrail participants with diabetes or higher HbA1c also experienced more rapid deterioration of frailty level with aging. This observation could reflect a role of diabetes complications in frailty trajectories or earlier shared determinants that contribute to diabetes and frailty risk in later life.
HbA<sub>1c</sub> level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
Authors: Marcus Lind, Aldina Pivodic, Ann-Marie Svensson, Arndis F Ólafsdóttir, Hans Wedel, Johnny Ludvigsson
Journal: BMJ (2019)

To evaluate if the lowest target level for glycated haemoglobin (HbA1c) of <6.5% is associated with lower risk for retinopathy and nephropathy than less tight control in children and adults with type 1 diabetes.Population based cohort study.Swedish National Diabetes Registry, 1 January 1998 to 31 December 2017.10 398 children and adults with type 1 diabetes followed from diagnosis, or close thereafter, until end of 2017.Relative risk (odds ratios) for retinopathy and nephropathy for different mean levels of HbA1c.Mean age of participants was 14.7 years (43.4% female), mean duration of diabetes was 1.3 years, and mean HbA1c level was 8.0% (63.4 mmol/mol). After adjustment for age, sex, duration of diabetes, blood pressure, blood lipid levels, body mass index, and smoking, the odds ratio for mean HbA1c <6.5% (<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol) for any retinopathy (simplex or worse) was 0.77 (95% confidence interval 0.56 to 1.05, P=0.10), for preproliferative diabetic retinopathy or worse was 3.29 (0.99 to 10.96, P=0.05), for proliferative diabetic retinopathy was 2.48 (0.71 to 8.62, P=0.15), for microalbuminuria or worse was 0.98 (0.60 to 1.61, P=0.95), and for macroalbuminuria was 2.47 (0.69 to 8.87, P=0.17). Compared with HbA1c levels 6.5-6.9%, HbA1c levels 7.0-7.4% (53-57 mmol/mol) were associated with an increased risk of any retinopathy (1.31, 1.05 to 1.64, P=0.02) and microalbuminuria (1.55, 1.03 to 2.32, P=0.03). The risk for proliferative retinopathy (5.98, 2.10 to 17.06, P<0.001) and macroalbuminuria (3.43, 1.14 to 10.26, P=0.03) increased at HbA1c levels >8.6% (>70 mmol/mol). The risk for severe hypoglycaemia was increased at mean HbA1c <6.5% compared with 6.5-6.9% (relative risk 1.34, 95% confidence interval 1.09 to 1.64, P=0.005).Risk of retinopathy and nephropathy did not differ at HbA1c levels <6.5% but increased for severe hypoglycaemia compared with HbA1c levels 6.5-6.9%. The risk for severe complications mainly occurred at HbA1c levels >8.6%, but for milder complications was increased at HbA1c levels >7.0%.
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse
Authors: Liguo Zhang, Xuelian He, Xuezhao Liu, Feng Zhang, L. Frank Huang, Andrew S. Potter, Lingli Xu, Wenhao Zhou, Tao Zheng, Zaili Luo, Kalen P. Berry, Allison Pribnow, Stephanie M. Smith, Christine Fuller, Blaise V. Jones, Maryam Fouladi, Rachid Drissi, Zeng-Jie Yang, W. Clay Gustafson, Marc Remke, Scott L. Pomeroy, Emily J. Girard, James M. Olson, A. Sorana Morrissy, Maria C. Vladoiu, Jiao Zhang, Weidong Tian, Mei Xin, Michael D. Taylor, S. Steven Potter, Martine F. Roussel, William A. Weiss, Q. Richard Lu
Journal: Cancer Cell (2019)